Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

Publication

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

Journal Paper/Review - Nov 17, 2021

Peyrin-Biroulet Laurent, Hart Ailsa, Bossuyt Peter, Long Millie, Allez Matthieu, Juillerat Pascal, Armuzzi Alessandro, Loftus Edward V, Ostad-Saffari Elham, Scalori Astrid, Oh Young S, Tole Swati, Chai Akiko, Pulley Jennifer, Lacey Stuart, Sandborn William J, HICKORY Study Group

Citation

Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 7:128-140.

Type

Journal Paper/Review (English)

Journal

Lancet Gastroenterol Hepatol 2021; 7

Publication Date

Nov 17, 2021

Issn Electronic

2468-1253

Pages

128-140

Brief description/objective

Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-tumour necrosis factor (TNF) agents.